
The foundation concentrates almost exclusively on funding pharmaceutical patient assistance programs that provide prescription medications to qualifying individuals, with virtually all giving directed to a single administrative recipient. Grants are very large and programmatic, aimed at sustaining medication access/affordability for uninsured or underinsured patients rather than a broad portfolio of nonprofits. Nonprofits that operate patient assistance, prescription access, or medication navigation programs would be the most natural fit.
Very large, centralized programmatic funding to a single or very small number of recipients to administer drug assistance; few grants overall.
Notable grantees: Under the Health Insurance Portability and Account
Bayer US Patient Assistance Foundation’s recent giving is defined by a single purpose: providing pharmaceutical assistance to qualifying individuals through a recurring administrative recipient. Its three largest recent grants, in 2023, 2024, and 2025, all went to Under the Health Insurance Portability and Account, each described as support to provide pharmaceutical assistance to qualifying individuals. That pattern points to a funder built around prescription access rather than a broad nonprofit portfolio. The foundation’s work centers on direct, means-tested support for patients who need prescription medications. In the recent-grants data, the recipient appears as an administrative vehicle in Whippany, NJ, which suggests a highly structured approach to sustaining patient assistance over time. The grants are unusually large for this kind of program support, reflecting the scale required to help cover medication access for eligible individuals. For researchers, the key signal is not a wide spread of causes, but concentration: repeated funding for the same pharmaceutical assistance purpose across multiple years, with all recorded grants landing in the United States.
The foundation’s clearest focus area is prescription drug assistance. In 2025, it gave $1,362,104,859 to Under the Health Insurance Portability and Account to provide pharmaceutical assistance to qualifying individuals, and the same purpose appears in its 2024 and 2023 grants as well. That repeated purpose places medication affordability at the center of its grantmaking. Rather than funding a mix of unrelated programs, the foundation appears to direct resources toward a single service model tied to access for eligible patients. The beneficiary side is also specific: qualifying individuals and patients requiring prescription medications. The stated grant purpose indicates direct support for medication costs, with the grant structure aligned to pharmaceutical access programs and medication cost subsidies. Across the recent record, there is one consistent theme: support for patient assistance that helps people obtain prescription drugs.
The foundation’s recent grants are very large, with a p25 of $730,589,219, a median of $915,173,087, and a p75 of $1,138,638,973. That size profile matches a program built to sustain substantial pharmaceutical assistance rather than smaller project grants. The recipient pattern is highly repetitive: the same administrative grantee appears in 2023, 2024, and 2025, each time for the same purpose. The foundation is a regular funder, not a DAF, and it does not make program-related investments. The grant record suggests restricted support tied to an ongoing assistance structure rather than an open application process.
$2.8B
$313M
$1.5B
$1.4B
Most grants fall between $730.6M and $1.1B, with a median of $915.2M.
25th Percentile
$730.6M
Median
$915.2M
75th Percentile
$1.1B
About 100% of grants go to recipients in NJ.
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Grantmaking is geographically concentrated in New Jersey. All recorded recent grants went to recipients in the HQ state, and the top state by grant count is NJ. The recipient location shown in the recent grants is Whippany, NJ. The country distribution is entirely U.S.-based, with 3 grants to U.S. recipients and no non-U.S. recipient countries in the recent record.
It funds pharmaceutical assistance for qualifying individuals. The recent grants all use the same purpose language: provide pharmaceutical assistance to qualifying individuals. The beneficiary profile centers on patients requiring prescription medications and means-tested assistance.
The grant size profile is very large. The p25 is $730,589,219, the median is $915,173,087, and the p75 is $1,138,638,973. The recent grants shown are all in the hundreds of millions of dollars.
In the recent grants data, no. The recipient country distribution is 100% U.S., with 3 grants to U.S. recipients.
It appears recurring. The same recipient and same pharmaceutical-assistance purpose show up in 2023, 2024, and 2025, indicating a repeated annual pattern rather than isolated one-off grants.
It is a regular funder and does not make program-related investments. The grant record points to restricted program support directed to an administrative recipient in Whippany, NJ, rather than a broad open-call grant program.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| Under the Health Insurance Portability and Account | WHIPPANY, NJ | $1,362,104,859 | 2025 | Provide pharmaceutical assistance to qualifying individuals |
| Under the Health Insurance Portability and Account | WHIPPANY, NJ | $915,173,087 | 2024 | Provide pharmaceutical assistance to qualifying individuals |
| Under the Health Insurance Portability and Account | WHIPPANY, NJ | $546,005,351 | 2023 | Provide pharmaceutical assistance to qualifying individuals |
Under the Health Insurance Portability and Account
$1,362,104,859Provide pharmaceutical assistance to qualifying individuals
Under the Health Insurance Portability and Account
$915,173,087Provide pharmaceutical assistance to qualifying individuals
Under the Health Insurance Portability and Account
$546,005,351Provide pharmaceutical assistance to qualifying individuals